None listed
Conditions
Interventions
Medical Device : Hyperbaric oxygen therapy will be treated for a total of 10 sessions, and 1 session will be performed every day. One session is to inhale more than 99.5% of oxygen with a mask at 2ATA
Sponsors
Myongji Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Subjects who have passed more than 12 weeks from the date of diagnosis of COVID-19 infection by RT-PCR or expert rapid antigen test 2) Subjects whose fatigue symptoms newly occurred within 6 months after COVID-19 was confirmed and continues to this day, and who scored 4 or more on the Chalder Fatigue scale (CFS) 3) Adults aged 20 to 69 years old 4) ECOG (Eastern Cooperative Oncology Group) PS of 0 or 1 5) Subjects (or legal representatives) agree to participate before clinical trial begins and provide informed written consent 6) Those who can read Korean
Exclusion criteria
Exclusion criteria: 1) Brain disease: Subjects with brain disease including dementia, stroke, epilepsy, and head trauma with loss of consciousness 2) Cardiac disease: Subjects with ischemic heart disease, heart failure, uncontrolled symptomatic arrhythmias, or those who have suggestive findings with the relevant disease based on electrocardiogram (ECG) and chest x-ray examination performed before clinical trials 3) Lung disease: Subjects with a history of chronic obstructive pulmonary disease (COPD), emphysema, asthma, pneumothorax, or chest surgery, and those with findings suggesting the corresponding disease on chest x-ray or before clinical trials. 4) Upper respiratory infection: Subjects with symptoms suggesting upper respiratory infection, such as fever of 38 degrees or higher, cough, sore throat, nasal congestion, runny nose, etc. at the time of participating in hyperbaric oxygen therapy. 5) Otology disease: Subjects who may have problems with ear pressure control, such as otitis media, severe rhinitis, and a history of barotrauma 6) Cancer (malignant tumor): Subjects with a history of malignant disease that is currently ongoing or has required active treatment within the past year. Participation in the study is possible if the subject has been in a stable condition without disease recurrence for more 1 year after complete cure. Note: Subjects with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., ductal carcinoma in situ and cervical carcinoma in situ) who have received potentially curative treatment are not excluded if treatment is completed within 6 months. 7) Subjects who are confirmed to be alcohol or drug dependent within 4 weeks before participation in the study 8) Subjects who have been diagnosed with schizophrenia or has a mental illness that cannot be controlled at the opinion of investigator 9) Subjects who cannot receive hyperbaric oxygen therapy due to claustrophobia 10) Subjects with a diagnosis of immunodeficiency or receiving long-term systemic steroid treatment (dose exceeding the equivalent of 10 mg of prednisone per day) or subjects who have received any form of other immunosuppressive treatment within 7 days prior to clinical trial treatment Note: If it is undergoing a reduction in steroid for discontinuation during the screening period, they are not excluded from the study. 11) Women who are currently pregnant 12) The subject is currently participating in a trial for clinical investigational medical devices, or clinical investigational drugs or medical devices within 4 weeks prior to participating in this study 13) Subjects who have received hyperbaric oxygen therapy after diagnosed COVID-19 infection 14) Subject has had major surgery within 2 weeks before participating in the clinical trial or did not recover from any effects of major surgery 15) Subject is unlikely to comply with the study procedures and limitations and requirements of the study in the opinion of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CFS (Chalder Fatigue scale) score | — |
Secondary
| Measure | Time frame |
|---|---|
| Neurocognitive Function Test score(Verbal Learning Test , Trail Making Test, Stroop test, Digit span test, MOCA-K (Montreal Cognitive Assessment);Psychiatric Symptom Questionnaire(HADS(Hospital Depression and Anxiety Scale) score, IES-K (Impact of Event Scale) score, PSQI (Pittsburgh Sleep Quality Index) score);Immune markers(ESR, CRP, Cytokine (IL-2,6,8,10));symptoms of COVID-19;Adverse events | — |
Countries
Korea, Republic of
Contacts
Public ContactYun-Jung Go
Myongji Hospital
Outcome results
None listed